CellBiophysicsPeer-reviewed journal article
Nuclear Phase Separation Drives NPM1-mutant Acute Myeloid Leukemia
Gandhar K. DatariD, Elmira KhabushevaiD, Archish Anand, Joshua Beale, Marwa Sadek, Chun-Wei David CheniD, Evdokiia PotolitsynaiD, Nayara Sousa de Alcântara-ContessotoiD, Guangyuan LiuiD, Josephine De La Fuente, Christina Dollinger, Anna G. Guzman, Alejandra G. Martell, Katharina WohlaniD, Abhishek MaitiiD, Nicholas James ShortiD, S. Stephen YiiD, Vibeke AndreseniD, Bjørn Tore GjertseniD, Brunangelo FaliniiD, Rachel E. RauiD, Lorenzo BrunettiiD, Nidhi SahniiD, Margaret A. GoodelliD, Joshua A. RibackiD
Abstract
During cancer development, mutations promote gene expression changes that cause transformation. Leukemia is frequently associated with aberrant HOXA expression driven by translocations in nucleoporin genes or KMT2A, and mutations in NPM1. How disparate mutations converge on this regulatory pathway is not understood. Here we demonstrate that mutant NPM1 (NPM1c) forms nuclear condensates in multiple human cell lines, mouse models, and primary patient samples. We show NPM1c phase separation is necessary and sufficient to coordinate the recruitment of NUP98 and KMT2A to condensates. Through extensive mutagenesis and pharmacological destabilization of phase separation, we find that NPM1c condensates are necessary for regulating gene expression, promoting in vivo expansion, and maintaining the undifferentiated leukemic state. Finally, we show that nucleoporin and KMT2A fusion proteins form condensates that are biophysically indistinguishable from NPM1c condensates. Together, these data define a new condensate underlying leukemias that we term coordinating bodies (C-bodies), and propose C-bodies as a therapeutic vulnerability.
- Citations
- 24
- FWCI
- 17.73
- Field percentile
- top 1%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Nucleophosmin mutations lead to abnormal, but reversible, nucleoli architecture and aggregate formation - implications for NPM1-targeting therapies in AML
Martin A. Grundy, Kellie Lucken, … Claire Seedhouse·Journal of Cell SciencePeer-reviewed·Apr 22, 2025
- Novel Strategy against AML by Rescuing Loss of Phase Separation of Pathogenic NPM1c
Yuting Zhu, Weifan Xu, … Pilong Li·bioRxiv·Apr 8, 2025
- Caspase-2 is essential for proliferation and self-renewal of nucleophosmin-mutated acute myeloid leukemia.
D. Sakthivel, A. N. Brown-Suedel, … L. Bouchier-Hayes·bioRxiv·May 29, 2023
- Prolonged XPO1 inhibition is essential for optimal anti-leukemic activity in NPM1-mutated AML
G. Pianigiani, A. Gagliardi, … L. Brunetti·bioRxiv·Dec 11, 2021
- Phase-separated nuclear bodies of nucleoporin fusions, SET-NUP214 and NUP98-HOXA9, promote condensation of MLL1 and CRM1 to activate target genes
- MOZ and HBO1 Histone Acetyltransferase Complexes Are Molecular Dependencies and Therapeutic Targets in NUP98-Rearranged Acute Myeloid Leukemia
Nicole Lynn Michmerhuizen, Emily Heikamp, … Charles Grenfell Mullighan·Cancer DiscoveryPeer-reviewed·Jun 19, 2025